Daré Bioscience (NASDAQ:DARE) Share Price Crosses Below 200-Day Moving Average – What’s Next?

Daré Bioscience, Inc. (NASDAQ:DARE)’s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.29 and traded as low as $2.88. Daré Bioscience shares last traded at $2.89, with a volume of 11,376 shares trading hands.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Daré Bioscience in a report on Tuesday, December 17th.

Daré Bioscience Price Performance

The company’s fifty day simple moving average is $3.07 and its 200-day simple moving average is $3.29. The firm has a market capitalization of $25.06 million, a PE ratio of -4.88 and a beta of 1.38.

Institutional Investors Weigh In On Daré Bioscience

Large investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in shares of Daré Bioscience in the fourth quarter worth about $52,000. Renaissance Technologies LLC increased its stake in Daré Bioscience by 6.7% during the fourth quarter. Renaissance Technologies LLC now owns 68,695 shares of the biotechnology company’s stock worth $214,000 after acquiring an additional 4,300 shares during the last quarter. Geode Capital Management LLC lifted its position in Daré Bioscience by 4.0% in the fourth quarter. Geode Capital Management LLC now owns 92,653 shares of the biotechnology company’s stock valued at $289,000 after buying an additional 3,593 shares during the last quarter. Finally, AMH Equity Ltd increased its position in shares of Daré Bioscience by 50.0% during the fourth quarter. AMH Equity Ltd now owns 150,000 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 50,000 shares during the last quarter. 6.70% of the stock is currently owned by hedge funds and other institutional investors.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.